Last updated 2026-06-18
- Went public, Apr 2006
- Raised $50M funding round, Nov 2021
- Raised $50M funding round, Dec 2015
Total raised
$149.1M
Last: 2021-11
Stage
Public
Founded
2006
Headcount
15
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences
About
Oramed Pharmaceuticals has developed a proprietary platform technology that allows for the oral delivery of drugs currently administered only via injection. The company's flagship product is an oral insulin capsule that has the potential to better the lives of millions of diabetics worldwide by enabling patients with type 2 diabetes to begin insulin therapy earlier, without needles.
Oramed's oral insulin is in advanced phase 3 clinical trials under the US FDA and the European EMA for the treatment of type 2 diabetes. In addition to oral insulin, the company's proprietary POD technology can potentially be used to orally administer a number of protein-based therapies that are presently available only via injection.
Funding history · 6 rounds · $149.1M total
2021-11
$50.0M
2018-07
$18.1M
2016-10
2015-12
2014-11
2013-01
Grant
$32K
Q&A
- What is Oramed Pharmaceuticals' primary focus?
- Oramed Pharmaceuticals specializes in developing a proprietary platform technology for the oral delivery of drugs that are currently administered via injection, with a flagship product being an oral insulin capsule for type 2 diabetes.
- When did Oramed Pharmaceuticals become a public company?
- Oramed Pharmaceuticals went public on NASDAQ in April 2006 and on TASE in July 2017.
- What is the current employee count for Oramed Pharmaceuticals?
- Oramed Pharmaceuticals has 11-50 employees.
- What was Oramed Pharmaceuticals' most recent funding round?
- In November 2021, Oramed Pharmaceuticals received a funding round of $50,000,000.
- What is the status of Oramed's oral insulin product?
- Oramed's oral insulin is in advanced phase 3 clinical trials under the US FDA and the European EMA for the treatment of type 2 diabetes.
- What was a significant financial event for Oramed Pharmaceuticals in March 2020?
- In March 2020, Oramed Pharmaceuticals priced a public offering of common stock for aggregate proceeds of $21,000,000 on NASDAQ.
- What strategic partnership did Oramed Pharmaceuticals enter into in January 2026?
- In January 2026, Lifeward entered a transformative strategic investment and partnership agreement with Oramed Pharmaceuticals to create a diversified biomedical innovation company.
- What was a key development for Oramed Pharmaceuticals in February 2025 regarding its oral drug delivery platform?
- In February 2025, Oramed Pharmaceuticals announced a transformative joint venture to accelerate the development and commercialization of oral insulin, forming a new standalone company, OraTech Pharmaceuticals Inc.
- What was a significant patent granted to Oramed Pharmaceuticals in May 2022?
- In May 2022, Oramed Pharmaceuticals was granted a U.S. combination therapy patent for oral GLP-1 & Insulin for the treatment of diabetes.
- What was the outcome of Oramed Pharmaceuticals' ORA-D-013-1 trial in January 2023?
- In January 2023, the ORA-D-013-1 trial failed to meet its endpoints, leading Oramed Pharmaceuticals to end its Type 2 Diabetes oral insulin efforts.
Team · 2
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2BB2CB2B2CB2G
Highlights
1 PatentsVerified
Tags
oral-drugsmedical-technologiespharmaceuticalsbiotechnologydrug-deliverydiabetespharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | oramed.com |
|---|---|
| linkedin.com/company/365036 | |
| facebook.com/oramed.pharmaceuticals | |
| YouTube | youtube.com/channel/UCbX6pFqc7itKkSnJjxKIdJg |
Identifiers & details
| Founded | 2006-3 |
|---|---|
| Employees (exact) | 15 |
| Offices | New York |
| Market cap | $113.7M |
| Status reason | Public on NASDAQ on Apr, 2006; Public on TASE on Jul, 2017 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2020-03 | $21.0M | |||
| 2017-07 | ||||
| 2012-09 | $1.0M | |||
| 2006-04 |